NEW YORK (GenomeWeb News) – Myriad Genetics said in its quarterly filing with the US Securities and Exchange Commission that it has leased approximately 8,300 square feet of lab and office space in Saranac Lake, NY. The lease expires in August 2017 and can be renewed for two additional five-year periods. The firm said it performs immunoassay development and manufacturing of kits at the facility.
Sequenta said this week that its LymphoSight platform will be used in a Phase II study of a drug for mantle cell lymphoma being conducted by the Eastern Cooperative Oncology Group. The LymphoSight platform utilizes an assay for amplification and sequencing of immunoglobulin and T cell receptors. It will also be compared to flow cytometry in its ability to detect prognostic markers.
Dow AgroSciences, a subsidiary of Dow Chemical, today said that it will collaborate with the Australian Centre for Plant Functional Genomics aimed at developing new traits for crop improvement. The partners will use their trait discovery and development capabilities to create plants with improved environmental stress response and agronomic performance.
EA, the genomics services provider formerly known as Expression Analysis that was recently acquired by Quintiles, said this week that it has awarded RNA-Seq grants to researchers at Brigham & Women's Hospital, Washington University in St. Louis, and Erasmus Medical College. Each of the grant winners will receive EA next-generation sequencing and bioinformatics services from EA, while Illumina will provide the next-generation sequencing products, and Golden Helix will provide data analysis solutions.
In Brief This Week is a Friday column containing news items that our readers may have missed during the week.